Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Idec receives accelerated equity funding from Genentech, patent license from Xoma for anti-CD20 MAb.

  • News

Executive Summary

GENENTECH ACCELERATES FUNDING SCHEDULE FOR IDEC-C2B8 COLLABORATION in anticipation of positive interim results from a pivotal trial of the Idec anti-CD20 monoclonal antibody in non-Hodgkin's B-cell lymphoma. Idec will present results from the first 50 patients of a planned 150 patients in a Phase III trial of IDEC-C2B8 May 21 to the American Society of Clinical Oncology annual meeting in Philadelphia.

Table

View full table

Tags:
Latest Headlines

US FDA Advisory Committee Reform Includes A Public Listening Session

EU CHMP Opinions And MAA Updates

MHRA Needs ‘Rebuilding’ After Post-Brexit Loss Of Capacity & Industry Investment

EU & South Korea Sign Deal On Exchange Of Confidential Information

See All
UsernamePublicRestriction

Register

PS028169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By